Eqis Capital Management Has Lifted Its Position in Open Text (OTEX) by $1.63 Million as Stock Declined; Biogen (BIIB) Share Value Declined While Gateway Investment Advisers Has Cut Position

Biogen Inc. (NASDAQ:BIIB) Logo

Gateway Investment Advisers Llc decreased its stake in Biogen Inc (BIIB) by 6.45% based on its latest 2018Q3 regulatory filing with the SEC. Gateway Investment Advisers Llc sold 8,334 shares as the company’s stock declined 6.12% with the market. The institutional investor held 120,863 shares of the biological products (no diagnostic substances) company at the end of 2018Q3, valued at $42.70M, down from 129,197 at the end of the previous reported quarter. Gateway Investment Advisers Llc who had been investing in Biogen Inc for a number of months, seems to be less bullish one the $67.14B market cap company. The stock increased 0.61% or $2.02 during the last trading session, reaching $333.21. About 1.32M shares traded. Biogen Inc. (NASDAQ:BIIB) has declined 0.04% since January 12, 2018 and is downtrending. It has underperformed by 0.04% the S&P500. Some Historical BIIB News: 23/04/2018 – New SPINRAZA® (nusinersen) Data Unveiled at AAN Annual Meeting Show Continued Improvement in Motor Function for Broad Age Rang; 01/05/2018 – Biogen Will Pay $50 Million To Reduce Royalties On Alzheimer’s Disease Drug — MarketWatch; 12/03/2018 – Biogen Announces New Interim Phase 2 Results From NURTURE; 05/04/2018 – Biogen and Samsung Bioepis Agree to Settlement with AbbVie Allowing Commercialization of IMRALDI™ (Adalimumab Biosimilar) in Europe; 20/04/2018 – Biogen: Will Have Option to License Therapies From Collaboration, Will Be Responsible for Their Development and Commercialization; 12/03/2018 – Biogen To Buy Schizophrenia Treatment From Pfizer For Up To $590 Million — MarketWatch; 01/05/2018 – BIIB TO MAKE 1-TIME $50M PAYMENT TO NEURIMMUNE FOR 5% REDUCTION; 24/04/2018 – BIOGEN INC QTRLY NON-GAAP DILUTED EPS $6.05; 25/05/2018 – Biogen’s Avonex Sales Rise; Multiple Sclerosis Market Up 1%; 10/05/2018 – @JimCramer vets biotech giants Biogen, Celgene, Gilead and Regeneron for positive prospects

Eqis Capital Management Inc increased its stake in Open Text Corp (OTEX) by 264.67% based on its latest 2018Q3 regulatory filing with the SEC. Eqis Capital Management Inc bought 41,728 shares as the company’s stock declined 13.24% with the market. The institutional investor held 57,494 shares of the edp services company at the end of 2018Q3, valued at $2.26 million, up from 15,766 at the end of the previous reported quarter. Eqis Capital Management Inc who had been investing in Open Text Corp for a number of months, seems to be bullish on the $9.23B market cap company. The stock increased 0.06% or $0.02 during the last trading session, reaching $34.49. About 326,982 shares traded. Open Text Corporation (NASDAQ:OTEX) has risen 3.12% since January 12, 2018 and is uptrending. It has outperformed by 3.12% the S&P500. Some Historical OTEX News: 02/04/2018 – Open Text Names Madhu Ranganathan CFO; 30/05/2018 – OPENTEXT REPORTS REPRICING & AMENDMENT OF CREDIT LINES; 09/05/2018 – Open Text 3Q EPS 22c; 09/05/2018 – OPEN TEXT CORP OTEX.TO – ANNOUNCING A 15% INCREASE TO QUARTERLY CASH DIVIDEND TO $0.1518 PER SHARE; 30/05/2018 – OPENTEXT ANNOUNCES REPRICING AND AMENDMENT OF CREDIT FACILITIES; 15/05/2018 – OpenText to Bring Security to the Edges of the Network and Beyond; 09/05/2018 – OPENTEXT BOOSTS QTR DIV BY 15%; 10/05/2018 – OPEN TEXT CORP OTEX.TO : BARCLAYS RAISES TARGET PRICE TO C$59 FROM C$57; 09/05/2018 – OPEN TEXT 3Q ADJ EPS 54C, EST. 62C; 09/05/2018 – Open Text 3Q Rev $685.9M

More notable recent Biogen Inc. (NASDAQ:BIIB) news were published by: Nasdaq.com which released: “Alkermes, Biogen Submit NDA to FDA for Multiple Sclerosis Drug – Nasdaq” on December 18, 2018, also Seekingalpha.com with their article: “Biogen down 5%, sell-siders soften outlook – Seeking Alpha” published on December 18, 2018, Benzinga.com published: “Sell-Side Roundup: What’s Next For For Applied Genetic (NASDAQ:AGTC) After 50% Plunge? – Benzinga” on December 13, 2018. More interesting news about Biogen Inc. (NASDAQ:BIIB) were released by: Nasdaq.com and their article: “Noteworthy Tuesday Option Activity: BA, BIIB, BHF – Nasdaq” published on December 18, 2018 as well as Investorplace.com‘s news article titled: “7 Pharmaceutical Stocks That Just Raised Prices This Year – Investorplace.com” with publication date: January 11, 2019.

Investors sentiment decreased to 1.01 in Q3 2018. Its down 0.01, from 1.02 in 2018Q2. It turned negative, as 45 investors sold BIIB shares while 334 reduced holdings. 138 funds opened positions while 243 raised stakes. 167.21 million shares or 1.69% less from 170.10 million shares in 2018Q2 were reported. Bedrijfstakpensioenfonds Voor De Media Pno reported 40,000 shares. Balasa Dinverno & Foltz Limited stated it has 1,786 shares. Pub Sector Pension Invest Board holds 0.02% or 9,428 shares. California-based Montecito National Bank And Trust has invested 0.09% in Biogen Inc. (NASDAQ:BIIB). Finemark Bank has 0.03% invested in Biogen Inc. (NASDAQ:BIIB). Garde Inc, a Washington-based fund reported 1,549 shares. Zeke Advsr Limited reported 0.24% in Biogen Inc. (NASDAQ:BIIB). Vantage Invest Advisors Ltd Limited Liability Company invested in 0.01% or 172 shares. Interest Limited Ca owns 5,484 shares or 0.6% of their US portfolio. Gp Inc holds 7,000 shares. 1,860 are owned by Pictet Cie (Europe) Sa. 641 are owned by Benjamin F Edwards Incorporated. Bailard Incorporated holds 2,190 shares. 423,038 were reported by Nordea Investment Management Ab. Oregon Pub Employees Retirement Fund holds 0.25% or 51,620 shares.

Since September 26, 2018, it had 0 insider purchases, and 1 insider sale for $350,000 activity.

Analysts await Biogen Inc. (NASDAQ:BIIB) to report earnings on January, 29 before the open. They expect $6.72 earnings per share, up 27.76% or $1.46 from last year’s $5.26 per share. BIIB’s profit will be $1.35B for 12.40 P/E if the $6.72 EPS becomes a reality. After $7.40 actual earnings per share reported by Biogen Inc. for the previous quarter, Wall Street now forecasts -9.19% negative EPS growth.

Among 35 analysts covering Biogen Idec Inc. (NASDAQ:BIIB), 27 have Buy rating, 0 Sell and 8 Hold. Therefore 77% are positive. Biogen Idec Inc. had 147 analyst reports since July 23, 2015 according to SRatingsIntel. The firm has “Neutral” rating given on Wednesday, May 2 by Citigroup. Bernstein maintained the shares of BIIB in report on Tuesday, April 10 with “Buy” rating. H.C. Wainwright maintained the shares of BIIB in report on Friday, January 26 with “Buy” rating. The stock of Biogen Inc. (NASDAQ:BIIB) has “Buy” rating given on Wednesday, April 25 by Robert W. Baird. The firm has “Buy” rating given on Wednesday, January 31 by UBS. As per Wednesday, August 30, the company rating was maintained by Jefferies. The company was upgraded on Wednesday, October 25 by BMO Capital Markets. The stock of Biogen Inc. (NASDAQ:BIIB) has “Buy” rating given on Wednesday, October 25 by H.C. Wainwright. Jefferies reinitiated the shares of BIIB in report on Tuesday, July 11 with “Hold” rating. The firm has “Hold” rating by BMO Capital Markets given on Monday, July 17.

Gateway Investment Advisers Llc, which manages about $12.58B and $11.92B US Long portfolio, upped its stake in Paypal Hldgs Inc by 6,001 shares to 674,756 shares, valued at $59.27M in 2018Q3, according to the filing. It also increased its holding in Hilton Worldwide Hldgs Inc by 31,863 shares in the quarter, for a total of 292,323 shares, and has risen its stake in Prologis Inc (NYSE:PLD).

Among 12 analysts covering OpenText Corporation (NASDAQ:OTEX), 10 have Buy rating, 1 Sell and 1 Hold. Therefore 83% are positive. OpenText Corporation had 27 analyst reports since July 30, 2015 according to SRatingsIntel. The firm has “Sell” rating by Macquarie Research given on Wednesday, November 22. As per Wednesday, November 22, the company rating was maintained by Raymond James. The rating was maintained by BMO Capital Markets with “Buy” on Thursday, August 3. The company was maintained on Monday, August 6 by Barclays Capital. The rating was maintained by Barclays Capital on Thursday, October 29 with “Overweight”. The company was maintained on Thursday, February 1 by Barclays Capital. The company was maintained on Friday, August 4 by Barclays Capital. The stock of Open Text Corporation (NASDAQ:OTEX) earned “Overweight” rating by Barclays Capital on Tuesday, July 28. The firm has “Buy” rating by BMO Capital Markets given on Wednesday, November 1. As per Thursday, February 1, the company rating was maintained by BMO Capital Markets.

Eqis Capital Management Inc, which manages about $779.38 million and $1.60B US Long portfolio, decreased its stake in Pimco Etf Tr (TUZ) by 25,456 shares to 508,599 shares, valued at $25.38M in 2018Q3, according to the filing. It also reduced its holding in Gilead Sciences Inc (NASDAQ:GILD) by 8,572 shares in the quarter, leaving it with 96,283 shares, and cut its stake in Oracle Corp (NYSE:ORCL).

More notable recent Open Text Corporation (NASDAQ:OTEX) news were published by: Nasdaq.com which released: “Open Text Corporation (OTEX) Ex-Dividend Date Scheduled for August 30, 2018 – Nasdaq” on August 29, 2018, also Seekingalpha.com with their article: “Open Text: One Of The Best Valued Tech Stocks – Seeking Alpha” published on September 21, 2018, Seekingalpha.com published: “Open Text (OTEX) Q1 2019 Results – Earnings Call Transcript – Seeking Alpha” on October 31, 2018. More interesting news about Open Text Corporation (NASDAQ:OTEX) were released by: Prnewswire.com and their article: “OpenText Streamlines Collaboration for Marketers – PRNewswire” published on December 19, 2018 as well as Seekingalpha.com‘s news article titled: “Open Text Is Opening New Doors – Seeking Alpha” with publication date: June 25, 2018.

Biogen Inc. (NASDAQ:BIIB) Ratings Chart